Category Specific RSS

Categories: News

New Google Education Partner status sends TALi shares soaring

Australian tech company TALi Digital (ASX: TD1) has secured mass global distribution following the announcement that the company has achieved Google For Education Partner status for their TALi education platform, sending TALi’s share price soaring 35%. 

Clinically tested software products which address neurological conditions in early childhood to strengthen cognitive attention in children, TALi Detect and TALiTrain will now be fully integrated into Google Classroom and Google-based touch screen devices. 

“Receiving this status significantly increases the potential availability for TALi solutions product suite and is a significant step forward in our expansion into the US market where the Google for Education platform is widely used and adoption of Chrome devices is substantial,” said TALi Managing Director, Glenn Smith. 

“These integrations help streamline the user experience by allowing the input of teacher, class and student data directly into our platform, making the onboarding process as seamless as possible,” 

Securing the new Google For Education Status will play a major role in TALi’s penetration into the United States market where Google dominates the education sector with more than 55 percent of schools using Google products such as G-Suite, Google Education and Google Chromebooks. 

Globally, more than 90 million students, teachers and administrators use G-Suite for education. 

Accompanying Partner status is marketing support, partnership branding support and developer support from Google as well as key security function integration via Google Sign In. 

Previously operating under the name Novita Healthcare (ASX: NHL), the company underwent a re-brading to TALi Digital (ASX: TD1) in December 2019 to align with their flagship product – TALi – which combines evidence based algorithms inside a game-based program to assess and strengthen core attention in early childhood. 

Shares in TALi surged to an intra-day high of $0.069 in early morning trade, a rise of 35.2% on the previous day’s close price of $0.51.

Alfred Chan

Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.

Recent Posts

Control Bionics Moves to Fully Acquire NeuroBounce Program as EMG-Based Performance Tech Gains Momentum

As interest in neuromuscular activation tools accelerates across elite sport, Control Bionics Limited (ASX:CBL) is…

15 hours ago

SKS Technologies Moves to Expand NSW Footprint With Delta Elcom Acquisition

Australia’s data-centre construction sector continues to surge on the back of cloud adoption, AI-driven computing…

2 weeks ago

Monash University Partners with HITIQ to Advance Concussion Science Using Smart Mouthguards

A major Australian research initiative is set to push forward global understanding of brain injury,…

4 weeks ago

Harris Technology targets return to profitability amid surging Refurbished Tech sales and Apple expansion

Following a successful FY25 which saw a boost in gross profit after launching its refurbished…

1 month ago

Pivotal Metals Secures $5.4M to Fast-Track Quebec Drill Program

Pivotal Metals (ASX:PVT) has locked in $5.4 million in fresh funding to accelerate exploration across…

1 month ago

Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise

Biotech company Biotron Limited (ASX:BIT) has announced a bold step into the anaesthetics sector, acquiring…

2 months ago